最新ニュース Celularity (NASDAQ:CELU) 株価情報

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Earnings

Earnings Beats

Earnings Misses

News

FTLF

FitLife Brands Q1 EPS $0.20 Misses $0.29 Estimate, Sales $15.94M Beat $15.77M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cadrenal.com%2F&amp;esheet=54255465&amp;newsitemid=20250515408603&amp;lan=en-US&amp;anchor=Cadrenal+Therapeutics%2C+Inc.&amp;index=1&amp;md5=eb57e3bf892902967f302bae6cefbdca">Cadrenal Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy.
Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently underway.

CVKD

Cadrenal Therapeutics Announces Manufacturing And Supply Chain Milestones For Tecarfarin, Oral VKA Anticoagulant Designed To Address Unmet Needs In Anticoagulation Therapy

Needham analyst Ryan Koontz reiterates Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Buy and maintains $130 price target.

Price Target

Reiteration

Analyst Ratings

ANET

Needham Reiterates Buy on Arista Networks, Maintains $130 Price Target

NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) reported quarterly losses of $(0.05) per share. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported $14.53 million in sales this quarter. This is a 16.97 percent decrease over sales of $17.49 million the same period last year.

NXPL

NextPlat Q1 EPS $(0.05) Up From $(0.08) YoY, Sales $14.53M Down From $17.49M YoY

ELEV

Elevation Oncology Q1 EPS $(0.24) Misses $(0.19) Estimate

Health Care

General

CYBN

Cybin Engages Thermo Fisher To Support Phase 3 Supply And Potential Commercial Manufacturing Of CYB003 In Development For Major Depressive Disorder

Auxly Cannabis Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) reported quarterly earnings of $0.01 per share. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported $22.76 million in sales this quarter. This is a 21.53 percent increase over sales of $18.73 million the same period last year.

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

Auxly Cannabis Group Q1 GAAP EPS $0.01 Up From $(0.02) YoY, Sales $22.76M Up From $18.73M YoY

EDBL

Edible Garden AG Q1 EPS $(2.47) Beats $(3.03) Estimate, Sales $2.70M Miss $3.82M Estimate

Arthur Hayes, Chief Investment Officer of Maelstrom and co-founder of BitMEX on Thursday said that foreign capital repatriation and the devaluation of U.S. Treasury bonds will be the twin forces driving Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to $1 million within the <a href="https://in.benzinga.com/markets/25/05/45384424/great-progress-made-trump-says-traders-react-as-bitcoin-pops-then-stalls-at-key-resistance">next presidential cycle</a>.
What Happened: His thesis is rooted in structural imbalances in the U.S. trade and capital accounts and the political imperative to resolve them not through austerity, but through capital controls and money printing.
&#8220;Foreign capital repatriation and the devaluation of the gargantuan stock of U.S. treasuries will be the two catalysts that will power Bitcoin to $1 million sometime between now and 2028,&#8221; Hayes <a href="https://cryptohayes.substack.com/p/fatty-fatty-boom-boom">wrote</a>.
The essay dissects the growing tension between the U.S.'s reliance on foreign capital to finance its deficits and the political unwillingness to pursue hardline trade protectionism. 
Hayes argues that tariffs are an insufficient tool for rebalancing trade flows and are politically unsustainable in the short term, especially when they raise consumer prices. 
Instead, he predicts a shift to capital controls, specifically targeting the foreign ownership of U.S. financial assets like stocks, bonds and real estate.
Hayes envisions a 2% annual tax on foreign-owned financial assets, which he believes could generate enough revenue to eliminate income taxes for most U.S. households. 
"Trump could eliminate income taxes for the vast majority of voters by placing a 2% foreign capital tax on stocks, bonds, and property," he wrote.
This tax, he argues, would either discourage foreigners from accumulating U.S. assets, thus weakening the dollar and making U.S. exports more competitive, or allow capital inflows to continue while redistributing tax revenues domestically. 
"Either foreign capital stays, pays the tax, and revenue is used to eliminate income taxes… or foreign capital leaves, and American manufacturing grows," Hayes explained.
But foreign capital fleeing U.S. assets would have systemic implications. 
Hayes points out that the U.S. financial system is deeply reliant on steady demand for Treasury bonds, especially long-duration debt, and warns that a collapse in demand could trigger a surge in yields, destabilizing markets.
To counter this, Hayes predicts the Federal Reserve will resume quantitative easing (QE) and other expansionary measures to absorb the supply of Treasuries as foreign investors exit. 
"Bond prices will rise and yields collapse. The Fed will buy bonds due to its QE policy," he wrote.
In his view, this renewed round of money printing will debase U.S. debt and fiat savings, driving investors toward hard assets. 
Why It Matters: Hayes compares this to how U.S. Treasuries have already lost substantial purchasing power relative to Bitcoin and gold since 2021.
"Treasuries lost 64% and 84% of their value vs. gold and Bitcoin, respectively, from 2021 until the present," he stated, citing indexed ETF performance.
As the monetary system splinters under the weight of these imbalances, Hayes views Bitcoin as the only viable hedge for private capital. 
Unlike gold, which often requires intermediaries and custody solutions susceptible to regulatory interference, Bitcoin is a bearer asset that can be transferred without institutional permission.
&#8220;Bitcoin is the perfect and only lifeboat for global capital that must leave America and elsewhere,&#8221; Hayes declared.
He contends that even if 10% of the $33 trillion in foreign-owned U.S. portfolio assets were to rotate into Bitcoin, the price would not merely rise linearly but potentially explode due to constrained supply and liquidity. 
He envisions a potential "short squeeze of epic proportions" as traditional capital competes to enter the market.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45417306/michael-saylors-bitcoin-strategy-infinite-money-glitch-or-a-reflexive-leverage-bet">Michael Saylor&#8217;s Bitcoin Strategy—&#8217;Infinite Money Glitch&#8217; Or A Reflexive Leverage Bet?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Arthur Hayes Predicts Bitcoin To Hit $1 Million By 2028

Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(1.44) by 48.61 percent.

PVLA

Palvella Therapeutics Q1 EPS $(0.74) Beats $(1.44) Estimate

INKT

MiNK Therapeutics Q1 EPS $(0.70) Beats $(0.71) Estimate

Ark Invest founder Cathie Wood says American power bills might have been roughly 90% cheaper had Washington not tightened the regulatory vice on nuclear energy in the 1970s, citing new in-house research released this week.
What Happened: Wood on Wednesday reposted analyst Sam Korus's thread on X, highlighting an Ark chart that shows nuclear construction costs veering sharply upward after a wave of safety rules, while solar kept sliding, ultimately flipping the cost hierarchy.
The underlying study argues that, adjusted for capacity factors, pre-1975 cost trends would make nuclear the cheapest source of baseload power today and lop roughly nine-tenths off retail electricity prices.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">According to <a href="https://twitter.com/ARKInvest?ref_src=twsrc%5Etfw">@ARKInvest</a>'s research on nuclear energy led by <a href="https://twitter.com/skorusARK?ref_src=twsrc%5Etfw">@skorusARK</a>, if government regulators had not interfered, electricity costs would be roughly 90% lower in the US than they are today. <a href="https://t.co/njsS6CRjr5">https://t.co/njsS6CRjr5</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1922826011638399313?ref_src=twsrc%5Etfw">May 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Nuclear's fortunes changed after the partial meltdown at Three Mile Island in March 1979, which triggered sweeping design and training mandates from the newly strengthened Nuclear Regulatory Commission. Academic <a href="https://www.sciencedirect.com/science/article/pii/S254243512030458X?">reviews</a> by ScienceDirect and Breakthrough Journal <a href="https://www.breakthroughjournal.org/p/its-the-nuclear-regulation-stupid">show</a> that those rules added at least 25% to reactor capital costs and stretched build times by more than two years on average.
See also: <a href="https://www.benzinga.com/general/health-care/25/05/45431505/gop-tax-bill-breaks-trumps-social-security-tax-pledge-still-hits-25-million-seniors-while-elon-musks-stock-wealth-skirts-fica">GOP Tax Bill Breaks Trump&#8217;s Social Security Tax Pledge, Still Hits 25 Million Seniors While Elon Musk&#8217;s Stock Wealth Skirts FICA</a>
Industry studies estimate labor and materials outlays <a href="https://ifp.org/nuclear-power-plant-construction-costs">jumped</a> another 10-15% in the early 1980s, cementing the cost spiral. By contrast, levelized solar prices have fallen more than 80% since 2010, leaving nuclear stranded without regulatory relief.
Why It Matters: Wood's nuke-friendly stance dovetails with <a href="https://www.benzinga.com/markets/equities/24/10/41442870/cathie-woods-ark-invest-buys-3-95m-worth-of-amazon-stock-amid-companys-nuclear-moves">Ark's bets</a> on companies pursuing advanced reactors and on customers such as Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) that are exploring in-house nuclear supply for data-center demands.
Ark Invest&#8217;s research also arrives after news broke earlier this week of President Donald Trump advancing a <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom">series of executive orders</a> aimed at dramatically changing U.S. nuclear energy policy to accelerate the construction of new nuclear power plants and reduce regulatory barriers.
Nuclear power developer Elementl Power on Wednesday <a href="https://www.benzinga.com/news/25/05/45337965/google-to-fund-three-nuclear-sites-says-the-move-will-allow-them-to-move-at-the-speed-required-to-meet-this-moment-of-ai-and-american-innovation">also revealed</a> that it had signed a strategic agreement with Google to develop three sites for advanced reactors.
Photo courtesy: ChrisStock82 / Shutterstock.com
Read next: <a href="https://www.benzinga.com/markets/equities/25/05/45430137/trump-had-a-problem-with-tim-cook-president-says-he-told-apple-ceo-i-dont-want-you-building-in-india-amid-tariff-concerns-and-production-shift-from-china">Trump Had A &#8216;Little Problem&#8217; With Apple CEO Tim Cook, Says &#8216;I Don&#8217;t Want You Building In India&#8217;</a>

Equities

Markets

AMZN

Cathie Wood Says US Electricity Prices Would Be 90% Lower Without Three Mile Island–Era Rules

HC Wainwright &amp; Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) with a Buy and maintains $100 price target.

BLTE

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $100 Price Target

Needham analyst Bernie McTernan maintains Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) with a Buy and raises the price target from $60 to $70.

IBTA

Needham Maintains Buy on Ibotta, Raises Price Target to $70

Wells Fargo analyst Aaron Rakers upgrades Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Equal-Weight to Overweight and raises the price target from $72 to $75.

Upgrades

CSCO

Wells Fargo Upgrades Cisco Systems to Overweight, Raises Price Target to $75

Needham analyst Gil Blum maintains Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) with a Buy and lowers the price target from $11 to $10.

NKTX

Needham Maintains Buy on Nkarta, Lowers Price Target to $10

NVEE

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

Dick's Sporting Goods shares are trading lower after the company announced that it will acquire Foot Locker. Also, the company reported preliminary Q1 financial results.

William Blair analyst Sami Corwin downgrades Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) from Outperform to Market Perform.

Downgrades

William Blair Downgrades Nkarta to Market Perform

Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) reported quarterly losses of $(0.34) per share. This is a 67.31 percent increase over losses of $(1.04) per share from the same period last year. The company reported $110.31 thousand in sales this quarter. This is a 2.17K percent increase over sales of $4.86 thousand the same period last year.

POAI

CORRECTION: Predictive Oncology Q1 EPS $(0.34) Up From $(1.04) YoY, Sales $110.31K Up From $4.86K YoY

Press Releases

Celularity Inc. Announces Receipt of Nasdaq Notification

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Celularity Announces Publication of "Senescence, NK cells, and cancer: navigating the crossroads of aging and disease" in the April 4, 2025, Issue of Frontiers in Immunology

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Comments

Celularity

ニュース

最新ニュース Celularity (NASDAQ:CELU) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル